Aviva’s SpringWorks Therapeutics SWTX Stock Holding History

Aviva’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18,279	Closed	-$1.34M	–	971
2021 Q1	$1.34M	Buy	+18,279	New	+$1.43M	0.01%	742

Other funds holding SWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Aviva's SWTX Position: Q2 2021 in Review

Aviva sold out of SpringWorks Therapeutics (SWTX) in Q2 2021, closing a stake of 18,279 shares — an estimated $1.34M sold.

Aviva first reported a position in SWTX in Q1 2021 and held it in 1 quarter. The position peaked at $1.34M in Q1 2021. 135 funds tracked by Wall St. Rank hold SWTX as of Q2 2021.

Aviva reported no remaining SpringWorks Therapeutics position as of Q2 2021 after selling out during the quarter.
Aviva sold 18,279 SpringWorks Therapeutics shares in Q2 2021, an estimated $1.34M.
Aviva first reported a position in SpringWorks Therapeutics in Q1 2021 and held it in 1 quarter.
Aviva's SpringWorks Therapeutics position peaked at $1.34M in Q1 2021.
135 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.